Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Paul A. Friedman, M.D. to its Board of Directors.
“We are delighted to welcome Paul to the Verastem Board of Directors,” said Christoph Westphal, M.D., Ph.D., Verastem Executive Chairman.
Help employers find you! Check out all the jobs and post your resume.